SCHEMBL10000341

SCHEMBL10000341

COC(=O)c1cc(CBr)cc(OCc2cc(-n3c4ccccc4c4ccccc43)cc(-n3c4ccccc4c4ccccc43)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
MRGPRX4 Q96LA9 3/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.36
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
PRSS1 P07477 1/20 0.36
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HCRTR1 O43613 1/20 0.35
PAX8 Q06710 1/20 0.35
MAPK10 P53779 1/20 0.35
NPC1 O15118 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10000337 0.91 HPGD (0.41) LMNAHPGDMRGPRX4MEN1KMT2A
SCHEMBL13754821 0.84 F2 (0.39) MEN1KMT2AF2F10PRSS1
SCHEMBL13823282 0.83 MAOB (0.40) LMNAHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL13815330 0.79 F2 (0.35) LMNAMEN1KMT2ASMN1; SMN2F2
SCHEMBL986790 0.79 TSHR (0.48) LMNAHPGDMEN1KMT2AALDH1A1
SCHEMBL13815329 0.77 CNR2 (0.37)
SCHEMBL13754822 0.75 F2 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1F2
SCHEMBL4151119 0.74 PSEN1 (0.47) LMNAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL2176541 0.74 MAOB (0.50) LMNAHPGDMRGPRX4ALDH1A1MAPT
SCHEMBL10000340 0.74 KDM4E (0.52) HPGDMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124767-B2 Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2012-02-28 US disclosed
US-8124767-B2 Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2012-02-28 US disclosed
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-08-20 US disclosed
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same BTD, HLCS, BPGM LMNA 590/4885HPGD 1708/4885MRGPRX4 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.